CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

A new study from ChristianaCare’s Gene Editing Institute shows that disabling a single gene with CRISPR technology can ...

Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Scientists in China have genetically engineered a fungus that is widely used as a meat substitute, making it an even more ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Both stocks are risky, but one is far less so. Investors seeking stocks with explosive growth potential should consider the ...

Seq, a CRISPR-based method that enriches ultra-rare tumor DNA in blood by removing background wild-type DNA before sequencing ...

Gene therapy could be a permanent cure for many life-threatening hereditary diseases, and this will only help in the treatment of genetic diseases and cancer ...

Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...